Alkermes (ALKS) Cash from Investing Activities Growth (1y) (2011 - 2026)
Powered by 
Analysis
Alkermes (ALKS) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn | 93.92% |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn | -1.35% |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn | -627.53% |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | -38.43% |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn | -46.70% |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | -103.94% |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | - |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | -174.44% |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn | 129.18% |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | 91.75% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91.75% |
| Mar 31, 2026 | -22,919.16% |
| Dec 31, 2025 | 2,423.21% |
| Sep 30, 2025 | 93.84% |
| Jun 30, 2025 | -156.34% |
| Mar 31, 2025 | 122.78% |
| Dec 31, 2024 | 33.87% |
| Sep 30, 2024 | 8.40% |
| Jun 30, 2024 | -57.09% |
| Mar 31, 2024 | -154.84% |
| Dec 31, 2023 | -175.64% |
| Sep 30, 2023 | -1,441.41% |
| Jun 30, 2023 | 398.11% |
| Mar 31, 2023 | 220.13% |
| Dec 31, 2022 | 3,838.54% |
| Sep 30, 2022 | 128.06% |
| Jun 30, 2022 | -1,119.31% |
| Mar 31, 2022 | -60.72% |
| Dec 31, 2021 | 97.89% |
| Sep 30, 2021 | -285.40% |